Cholangiocarcinoma is the second most common primary liver cancer and responds poorly to existing therapies. Intrahepatic cholangiocarcinoma (ICC) likely originates from the biliary tree and develops within the hepatic parenchyma. We have generated a flexible orthotopic allograft mouse model of ICC that incorporates common genetic alterations identified in human ICC and histologically resembles the human disease. We examined the utility of this model to validate driver alterations in ICC and tested their suitability as therapeutic targets. Specifically, we showed that the fused-in-glioblastoma-c-ros-oncogene1 (FIG-ROS1(S); FIG-ROS) fusion gene dramatically accelerates ICC development and that its inactivation in established tumors has a potent antitumor effect. Our studies establish a versatile model of ICC that will be a useful preclinical tool and validate ROS1 fusions as potent oncoproteins and therapeutic targets in ICC and potentially other tumor types. C holangiocarcinoma, the second most common primary liver cancer, has a dismal prognosis due to its poor responsiveness to existing therapies. It represents 10-25% of primary liver cancers worldwide (1), but is more frequent in Asia, due to a higher prevalence of risk factors such as parasitic infections, biliary-duct cysts, hepatolithiasis, and primary sclerosing cholangitis (2). Intrahepatic cholangiocarcinoma (ICC) develops within the liver parenchyma, shows markers of cholangiocyte differentiation, including positivity for cytokeratin 19, and leads to abundant stromal desmoplasia. Whereas surgical resection can be curative, most patients are not eligible for this procedure due to advanced disease, and no effective systemic therapy has been developed to date (3, 4).
Cholangiocarcinoma is the second most common primary liver cancer and responds poorly to existing therapies. Intrahepatic cholangiocarcinoma (ICC) likely originates from the biliary tree and develops within the hepatic parenchyma. We have generated a flexible orthotopic allograft mouse model of ICC that incorporates common genetic alterations identified in human ICC and histologically resembles the human disease. We examined the utility of this model to validate driver alterations in ICC and tested their suitability as therapeutic targets. Specifically, we showed that the fused-in-glioblastoma-c-ros-oncogene1 (FIG-ROS1(S); FIG-ROS) fusion gene dramatically accelerates ICC development and that its inactivation in established tumors has a potent antitumor effect. Our studies establish a versatile model of ICC that will be a useful preclinical tool and validate ROS1 fusions as potent oncoproteins and therapeutic targets in ICC and potentially other tumor types.
C holangiocarcinoma, the second most common primary liver cancer, has a dismal prognosis due to its poor responsiveness to existing therapies. It represents 10-25% of primary liver cancers worldwide (1) , but is more frequent in Asia, due to a higher prevalence of risk factors such as parasitic infections, biliary-duct cysts, hepatolithiasis, and primary sclerosing cholangitis (2) . Intrahepatic cholangiocarcinoma (ICC) develops within the liver parenchyma, shows markers of cholangiocyte differentiation, including positivity for cytokeratin 19 , and leads to abundant stromal desmoplasia. Whereas surgical resection can be curative, most patients are not eligible for this procedure due to advanced disease, and no effective systemic therapy has been developed to date (3, 4) .
Sequencing efforts are beginning to generate in-depth information about the somatic alterations that occur in cholangiocarcinoma. Among the most frequently mutated genes are the tumor suppressor tumor protein p53 (TP53) (37-44%) (5, 6 ) and the kirsten rat sarcoma viral oncogene homolog (KRAS) (17-54%) (6) (7) (8) , although mutations in MLL3 and SMAD4 are also common (15% and 17% of cases, respectively) (6) . Despite their high mutational frequency, none of these signature genes is amenable to targeted therapy.
Recently, the mutational spectrum of cholangiocarcinoma has been extended by the identification of ROS1 fusions in nearly 9% of cholangiocarcinoma patients (9) . Oncogenic fusion kinases involving the orphan receptor tyrosine kinase ROS1 have been previously reported at low frequency in lung adenocarcinoma and glioblastoma and result from chromosomal rearrangements that lead to constitutive activation of the ROS1 kinase activity. Consequently, ROS1 presents a potential drug target for a subset of patients with ICC.
Mouse models have proven a powerful tool for understanding the relationship between cancer genetics and tumor behavior, but only a few genetically engineered mouse models (GEMMs) of ICC exist and many display a mixed ICC/hepatocellular carcinoma (HCC) histology (10) (11) (12) (13) . A histopathologically accurate ICC model has been produced by liver-specific expression of endogenous Kras G12D mutant in combination with Tp53 tumor suppressor gene deletion (14) . Still, as with other multiallelic GEMMs, this model requires time-consuming and expensive breeding strategies to integrate further genetic changes. Moreover, because the conditional alleles cause the alteration to be present throughout the entire organ, the majority of GEMMs do not recapitulate the human microenvironment where cancer cells and normal cells are both present and interact. Faster and more flexible in vivo models would greatly facilitate the functional characterization of candidate driver alterations and therapeutic targets, as well as produce tractable preclinical models for testing novel therapies.
Our laboratory has previously established an orthotopic allograft mouse model for hepatocellular carcinoma that is based on the genetic manipulation of liver progenitor cells followed by the orthotopic transplantation into recipient mice (15, 16) . This model enabled us to rapidly study genetic interactions during tumorigenesis as well as to identify and functionally validate tumor suppressor genes and oncogenes. Here we describe the development of a similar model for ICC that allows Significance Intrahepatic cholangiocarcinoma (ICC) is a fatal yet understudied primary liver malignancy. To accelerate the functional annotation of cancer genes and therapeutic targets in this disease, we generate a highly flexible orthotopic allograft mouse model of ICC that can be easily modified in vitro to mimic either oncogene expression by retrovirus-mediated gene transfer or tumorsuppressor gene loss by using RNA interference technology. We use this model to demonstrate that the fused-in-glioblastomac-ros-oncogene 1 (FIG-ROS) fusion, which is found in a subset of ICC patients, accelerates cholangiocarcinogenesis. Moreover, by using reversible gene expression, we show that FIG-ROS inactivation in carcinomas harboring mutant kirsten rat sarcoma viral oncogene homolog (Kras) and p53 mutations can potently inhibit tumor growth, thereby validating ROS as a therapeutic target in ICC.
us to rapidly interrogate biologically relevant aspects of this disease. We use this system to functionally validate FIG-ROS as a potent oncoprotein in ICC and document its requirement for tumor maintenance, thus confirming its potential as a therapeutic target.
Results

Differential Effects of c-Myc and Kras on Tumors Initiated from Liver
Progenitor Cells. Our previous progenitor-cell-based mouse model of liver cancer involved the isolation and the retroviral transduction of E-cadherin positive fetal liver cells from p53 −/− embryos with different oncogenes, followed by transplantation of the genetically modified cell populations into recipient mice. In an attempt to improve this model, we used a strategy to incorporate conditional mutant alleles exclusively in the hepatic parenchymal cells. Specifically, we generated mice harboring an Albumin-Cre (Alb-Cre) transgene together with two different conditional mutant p53 alleles (p53 lox and p53
lslR172H
, designated p53 lslR172H/lox ) (17, 18) (Fig. 1A) . As Alb-Cre is a liver-specific Cre-recombinase expressed in bipotent liver progenitor cells and adult hepatocytes (19) (20) (21) , its expression in the p53 lslR172H/lox background produces liver-specific expression of a mutant p53 and deletion of the other allele, which is a typical configuration occurring in human tumors.
Initially, to test whether oncogenes known to cooperate with p53 mutations would produce liver carcinomas in this model, we transduced fetal liver cells isolated from Alb-Cre; p53 lslR172H/lox embryos (subsequently referred to as AP cells) with retroviral vectors coexpressing green fluorescent protein (GFP) with either v-myc myelocytomatosis viral oncogene homolog (c-Myc) or Kras G12D . Following intrahepatic injection of the resulting cell populations, recipient mice rapidly developed tumors with complete penetrance (Fig. 1C) .
Surprisingly, the histopathology of tumors triggered by expression of c-Myc and oncogenic Ras was distinct. Consistent with previous work (15, 16) , tumors induced by c-Myc resembled human HCC, corroborated by strong nuclear expression of hepatic nuclear factor 4 alpha (HNF4A) and a granular, cytoplasmic reactivity with anti-hepatocyte paraffin-1 (Hep Par1), an antibody frequently used in the clinical diagnosis of HCC (Fig. 1E) ; conversely, they were negative for cytokeratin 19 (CK19), a marker for ductal differentiation. The histological spectrum of resulting HCCs ranked from pseudoglandular to solid carcinomas (Fig.  S1 ). In contrast, tumors induced by Kras G12D presented as a gland-forming adenocarcinoma. As is observed in human ICC, malignant epithelial cells were surrounded by a marked stromal desmoplasia that was not observed in tumors overexpressing cMyc ( Fig. 1 D and E) . Although this stromal reaction was triggered by the transplanted cells, it was derived from the host, as the stromal cells did not stain for the transduced GFP reporter. These results are consistent with the frequent occurrence of KRAS mutations in human ICC (6, 8) and their relative infrequent occurrence in HCC (22) and indicate that oncogenic Kras biases the malignant fate of transduced cell populations to ICC.
Development of an Orthotopic Allograft Model of ICC. The observations above and previous work suggested that it would be possible to produce an orthotopic allograft mouse model of ICC from liver progenitor cells simply incorporating mutant Kras instead of c-Myc. To achieve this and to eliminate the potential nonphysiological consequences of Kras overexpression, we introduced a cre-activatable endogenous Kras G12D allele (Kras lslG12D ) into our base configuration (23) . Next, isolated liver progenitor cells of the genotype Alb-Cre; Kras lslG12D ; p53 lslR172H/lox (subsequently referred to as AKP cells) were transduced with a GFP reporter and transplanted intrahepatically into recipient mice. The recipient animals succumbed to liver cancers with a median survival of 84 d, significantly longer than mice transplanted with AP cells overexpressing Kras G12D ( Fig. 1C , P = 0.045). In contrast, mice receiving AP cells transduced with a control plasmid did not develop liver tumors within 9 mo of follow-up. Thus, consistent with observations from strictly germ-line systems (14) , endogenous Kras G12D cooperated with p53 mutations in our model. Beyond large tumors in the liver, moribund animals harboring Kras G12D /mutant p53 tumors often displayed hemorrhagic ascites and/or breathing failure due to metastatic disease to the lung (Fig. S2) . Histologically, the GFP-expressing tumor cells were embedded in a GFP-negative and thus recipient-derived stroma rich in collagen fibers [ Fig stroma within the tumors (Fig. S3) . The epithelial tumor cells stained positive for CK19, a marker of ductal differentiation ( Fig. 2A) , and were in part mucin producing [confirmed by Alcian Blue stain ( Fig. 2A)] . Finally, the tumors were negative for HepPar1 ( Fig. 2A) , confirming they were not hepatocellular carcinoma. Overall, the model closely recapitulates histologic hallmark features of moderately differentiated cholangiocarcinoma in humans.
To determine whether perturbing an established cancer pathway might further alter the observed tumor phenotypes, we also transduced parallel populations with vectors expressing shorthairpin RNAs (shRNAs) targeting Pten (shPten) or a neutral control (shRenilla). Of note, the Pten shRNA potently suppresses target gene expression by RNA interference (24) , thereby deregulating the PI3K pathway and mimicking genetic changes that occur in ICC and many other cancer types (25) . Five weeks posttransplantation, recipient mice that had received Pten-suppressed AKP cells presented with a significantly increased tumor burden compared with mice transplanted with control transduced cells (Fig. 2B) . Importantly, whereas Pten suppression accelerated tumor growth compared with a control shRNA, it did not substantially alter the histology of resulting tumors (Fig. 2C) . These results illustrate the potential of the system to study cancer drivers while maintaining an accurate histology and, further, how shRNA technology can be incorporated to study loss-of-function phenotypes. Of note, experiments to document interactions between oncogenic Kras, mutant p53, and Pten inactivation using strictly germ-line strains would have required the intercrossing of six mutant alleles. (Fig. 4A) . Accordingly, CK19 expression remained positive and stromal desmoplasia was present. By marked contrast, all three tumors that arose in the absence of mutant Kras resembled HCC, confirmed by the presence and absence of HNF4α-and CK19 staining, respectively. These observations underscore the plasticity of the fetal liver-cell-based system and the linkage between tumor histopathology and driving genetic events (Fig. 4D) .
ROS triggers the phosphorylation of Shp2 and other effector proteins and exerts its function through multiple effectors, including components of the Jak/Stat, MAPK, and PI3K pathways (26) . Accordingly, tumor cell lines established from FIG-ROSexpressing tumors showed up-regulation of known ROS1 effectors such as pShp2 and pStat3 by immunoblotting, compared with control cell lines established from either tRFP-or shPtenexpressing tumors (Fig. 4C) . pAkt levels were elevated in both the FIG-ROS and the shPten cell lines, as expected. These cells rapidly formed lethal tumors that, at low passage, retained the histopathology of ICC upon retransplantation into recipient mice (Fig. 4B ). These observations confirm that the primary ICCs were indeed malignant and establish panels of genetically characterized tumors that can be used for preclinical studies to assess candidate ICC therapeutics. Two weeks after implantation, all mice (nine of nine) on dox developed measurable tumors and were randomized into two treatment arms: five mice continued on dox, whereas the remaining mice were returned to regular mouse chow (off dox).
These experiments decisively established the importance of FIG-ROS for cancer maintenance. Hence, whereas tumors in mice maintained on dox grew rapidly, tumors from mice switched to an off-dox diet remained stable until 5 wk postimplantation (Fig. 5D) . At this stage, masses derived from FIG-ROS-silenced tumors consisted of mostly cystic lesions harboring only small solid components that, histologically, were substantially less cellular than on-dox tumors and were dominated by the stromal compartment (Fig. 5E, H&E) . Of note, a control group of mice that was continuously kept off dox after transplantation did not develop measurable tumors until 7 wk postinjection.
The primary cellular response to FIG-ROS withdrawal appeared to be cell-cycle arrest, as observed by the reduced Ki67 staining within the remaining epithelial tumor cells in the doxwithdrawal cohort compared with on-dox samples (Fig. 5E) . Accordingly, FIG-ROS withdrawal in cultured tumor cells led to efficient down-regulation of ROS effector pathways accompanied by a reduction in colony formation in vitro (Fig. S4 A-C) . The fact that these advanced ICCs remained "addicted" to FIG-ROS expression was particularly surprising, given these tumor cells also harbored Kras and p53 mutations, and implies that human cholangiocarcinoma patients harboring the FIG-ROS fusion may greatly benefit from molecularly targeted therapy aimed at ROS1 fusions.
Discussion
Intrahepatic cholangiocarcinoma is a fatal yet understudied primary malignancy of the liver. To advance the understanding of the genetics and biology of this highly aggressive disease, we generated a genetically tractable mouse model of ICC that is based on the isolation and in vitro modification of fetal liver cells harboring Kras and p53 mutations, two of the most common genetic alterations found in human ICC (6) (7) (8) . We confirmed that tumors generated in this model closely resemble the histopathology of human ICC and display key characteristics like CK19 expression of the epithelial tumor cells and abundant stromal desmoplasia. We believe this is an important feature of the model as previous work from pancreas carcinoma-another glandular carcinoma also driven by KRAS mutations-indicates the stromal microenvironment has a major impact on cancer trajectory and treatment response (27) . Although recent advances in sequencing technologies have enabled in-depth characterization of the genomic landscape of human cancers, studies on the functional consequences of somatic mutations in cancer are necessary to understand the mechanistic impact of individual lesions and to identify candidate therapeutic approaches for targeting cancers of specific genotypes. The opportunity to genetically modify progenitor cells by retroviral gene transfer in vitro before transplantation allows for the rapid functional annotation of cancer genes and thus makes this mouse model much more flexible than those derived solely from germline alleles.
Beyond analysis of single genes, orthotopic allograft models enable in vivo pool-based screens for candidate oncogenes and tumor suppressor genes identified from genomic studies (28) (29) (30) , and it seems likely that this ICC model will be highly amenable to this approach. Moreover, because genetic alterations are exclusively introduced into the epithelial cells but not in the recipientderived stroma, the transplant approach may also serve as a valuable tool to investigate tumor-stroma interactions, with the fluorescent marker providing a convenient method to separate tumor and stromal compartments.
The Albumin-Cre used in our model becomes active in progenitor cells capable of differentiating into either the hepatocyte or bile duct lineage. Activation of Kras G12D using Alb-Cre produces a ductal adenocarcinoma with all of the features of ICC. In line with previous reports (15) , when these same progenitorenriched populations were transduced with c-Myc, the resulting tumors present as hepatocellular carcinoma. Apparently, Kras mutations predispose liver progenitor cells to ICC. Although the molecular basis underlying this observation remains unknown, the outcome is consistent with the observed incidence of these lesions in the human setting: increases in MYC copy number and/or expression are common in HCC, whereas activating mutations in KRAS are common in ICC. Of note, enforced expression of oncogenic Hras produces a mixed ICC/HCC model (31, 32) , further underscoring the impact of initiating oncogenic lesions to impact the histopathology of liver malignancies.
Initially identified in a glioblastoma cell line (33, 34) Although KRAS and TP53 mutations are among the most frequent genetic alterations in cholangiocarcinoma and other cancers, efforts to produce drugs targeting these mutations have proven unsuccessful. Our results imply that ROS1 inhibitors would be effective against a subset of human ICC harboring ROS1 fusion proteins. Although these events are relatively rare, small molecule inhibitors capable of inhibiting ROS1 kinase activity have been identified and are in clinical trials in lung cancer patients harboring tumors with ROS1 fusion events (35) . As more druggable targets are identified in cholangiocarcinoma through genomic or genetic approaches, we expect that this orthotopic allograft mouse model will provide a powerful platform to investigate their impact on the initiation and maintenance of the disease.
Materials and Methods
Generation of Liver Carcinomas. All animal experiments were performed in accordance with a protocol approved by the Memorial Sloan-Kettering Institutional Animal Care and Use Committee. Isolation, culture, and retroviral transduction of fetal liver cells have been described previously (15, 16) . Briefly, fetal liver cells were isolated by dispase digestion from developmental day14.5 mouse embryos, frozen, genotyped, and retrovirally transduced with MSCV-based vectors before orthotopic implantation. For subcapsular injection, the animals were anesthetized with isoflurane, and analgesia was provided by s.c. administration of buprenorphine directly before surgery. A subcostal transversal abdominal incision was performed and the left liver lobe was exposed. A total of 0.5-1 × 10 6 cells resuspended in 25 μL Matrigel were injected under the liver capsule using a Hamilton syringe and a 30-gauge needle. The injection site was sealed with Vetbond tissue adhesive (3M) and the abdominal wall was sutured using 4-0 Vicryl. The skin was closed with wound clips.
Doxycycline feed (625 mg/kg) purchased from Harlan Laboratories was replenished twice weekly. For orthotopic tumors, animals were killed when tumors reached a diameter of 10-15 mm as assessed by palpation or upon displaying signs of deterioration such as breathing failure or abdominal ascites. S.c. tumor volume was assessed by caliper measurements and calculated as 0.5 × length × width 2 (length > width).
Derivation of Tumor Cell Lines. Tumors were isolated, mechanically dissociated with a scalpel, and subsequently enzymatically digested in DMEM supplemented with collagenase (2 mg/mL; Sigma C5138) and DNase I (4 units/mL; Ambion 2222) for 60 min at 37°C in a shaking incubator (70 rpm). Crude digests were washed twice with PBS. For FACS, cells were stained with CD45-APC/Cy7 for 15 min at 4°C after performing ACK lysis (5 min at room temperature). To generate cell lines, enzymatic digests were plated in DMEM supplemented with 10% (vol/vol) FBS and penicillin/streptomycin onto gelatin-coated cell culture dishes. Cells were enriched for epithelial tumor cells by differential trypsinization or by FACS sorting for GFP.
Statistical Analysis. Statistical analysis was performed using GraphPad Prism software by applying the log-rank (Mantel-Cox) test to compare survival data and the unpaired two-tailed t test for all other experimental data.
